While follow-up studies (including in vivo studies) are needed, our findings suggest the potential efficacy of IGF1R inhibitors as a disease-targeted approach in preventing or managing BPH and its associated lower urinary tract symptoms. The gene discussed is IGF1R; the disease is benign prostatic hyperplasia.